Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation

Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced that its oral BRAF inhibitor, NXP200 (HSK42360), has received Breakthrough Therapy Designation from China's Center for Drug Evaluation for treating patients with BRAF V600-mutant, recurrent or progressive high-grade glioma. This designation may expedite the development and review process for the drug in China.